Professor, Pediatrics, Medical College of Wisconsin

Pediatric Hematology & Oncology

Cheryl A. Hillery, MD is an expert in the field of Pediatric Hematology & Oncology. She studied medicine at Duke University School of Medicine. Duke University School of Medicine is one of the top medical schools in the US. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. She received awards:"Super Doctor". Cheryl Hillery is a published doctor. She has 51 publications published. The most current publication "Potential therapeutic approaches for the treatment of vaso-occlusion in sickle cell disease."

Publications

---

• A multi-center randomized controlled trial of intravenous magnesium for Sickle cell pain crisis in children.
• Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation.
• Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with Sickle cell disease.
• Cold hypersensitivity increases with age in mice with Sickle cell disease.
• Intravenous magnesium for pediatric Sickle cell vaso-occlusive crisis: Methodological issues of a randomized controlled trial.
• Inhibition of Myeloperoxidase Decreases Vascular Oxidative Stress and Increases Vasodilatation in Sickle Cell Disease Mice.
• N-Acetyl Lysyltyrosylcysteine Amide Inhibits Myeloperoxidase, a Novel Peptide Based Inhibitor.
• Phosphatidylethanolamine is externalized at the surface of microparticles.
• A NOVEL HEMOGLOBIN-BINDING PEPTIDE REDUCES CELL-FREE HEMOGLOBIN IN MURINE HEMOLYTIC Anemia.
• Calcium-phosphate microprecipitates mimic microparticles when examined with flow cytometry.
• Patients with Sickle cell disease have increased sensitivity to cold and heat.
• Effects of Experimental Asthma on Inflammation and Lung Mechanics in Sickle Cell Mice.
• Transient receptor potential vanilloid 1 mediates pain in mice with severe Sickle cell disease.
• Methaemalbumin formation in Sickle cell disease: effect on oxidative protein modification and HO-1 induction.
• Pulmonary hypertension and NO in Sickle cell.
• Histopathology of experimentally induced asthma in a murine model of Sickle cell disease.
• Genetic endothelial systems biology of Sickle stroke risk.
• Pathology of Berkeley Sickle cell mice: similarities and differences with human Sickle cell disease.
• Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in Sickle cell disease.
• The effect of magnesium on length of stay for pediatric Sickle cell pain crisis.
• Hypoxia-induced acute lung injury in murine models of Sickle cell disease.
• Pathophysiology of stroke in Sickle cell disease.
• Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis.
• Patient-controlled analgesia for Sickle cell pain crisis in a pediatric emergency department.
• Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with Sickle cell disease.
• PECAM-1 negatively regulates GPIb/V/IX signaling in murine Platelets.
• Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit Sickle cell adhesion.
• Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis.
• Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with Sickle cell disease.
• L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and Sickle cell disease.
• Clinical and hematologic benefits of partial splenectomy for congenital hemolytic Anemias in children.
• Anion Exchange HPLC Isolation of High-Density Lipoprotein (HDL) and On-Line Estimation of Proinflammatory HDL.
• Bleeding Disorders: A common cause of menorrhagia in adolescents.
• Hydroxyurea therapy decreases the in vitro adhesion of Sickle erythrocytes to thrombospondin and laminin.
• Low-molecular-weight heparin in thrombotic Disease in children and adolescents.
• The carboxy-terminal cell-binding domain of thrombospondin is essential for Sickle red blood cell adhesion.
• Potential therapeutic approaches for the treatment of vaso-occlusion in Sickle cell disease.
• Type 2M von Willebrand Disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of v...
• Mechanisms of stroke in Sickle cell disease: Sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition.
• Hydroxyurea therapy in children severely affected with Sickle cell disease.
• Increased adhesion of erythrocytes to components of the extraCellular matrix: isolation and characterization of a red blood Cell lipid that binds thrombospondin and la...
• Unsuspected bruCellosis diagnosed in a child as a result of an outbreak of laboratory-acquired bruCellosis.
• Phosphorylation of human Platelet glycoprotein IIIa (GPIIIa). Dissociation from fibrinogen receptor activation and phosphorylation of GPIIIa in vitro.
• Fibrinogen binding to purified Platelet glycoprotein IIb-IIIa (integrin alpha IIb beta 3) is modulated by lipids.
• Activation-dependent changes in human Platelet PECAM-1: phosphorylation, cytoskeletal association, and surface membrane redistribution.
• D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma.
• Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with Sickle cell anaemia.
• Erythrocyte adhesion is modified by alterations in Cellular tonicity and volume.
• Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.
• Ca2+-CaM activation of AMP deaminase contributes to adenine nucleotide dysregulation and phosphatidylserine externalization in human Sickle erythrocytes.

Schools

---

• Duke University

• University Of North Carolina Hospitals

Conditions Treated

---

• Anemia
• Coagulation Disorders (incl. Hemophilia)
• Immune Thrombocytopenic Purpura (ITP)
• Qualitative Platelet Defects (incl. Glanzmann's Thrombasthenia)
• View All

Doctors Specialties

---

• Hematology
• Pediatric Hematology
• Oncology

Accepted Insurances

---

Awards

---

• Super Doctor

Education

---

• University of North Carolina Hospitals
• Duke University School of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Cheryl M. Cameron, MD This Doctor is OpenDoctor Recommended.
	Dr. Samir Mullick, MD This Doctor is OpenDoctor Recommended.
	Hillary L. McCown, APNP
	Rebecca R. Rusch, APNP
	Dr. Michael E. Keefe, MD This Doctor is OpenDoctor Recommended.
	Dr. Ehab Atallah, MD This Doctor is OpenDoctor Recommended.
	Dr. Sachin S. Jogal, MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher Chitambar, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Robert F. Taylor, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard L. Tower II, MD This Doctor is OpenDoctor Recommended.
	Dr. Meghen B. Browning, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas C. Abshire, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Bruce M. Camitta, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Varsha V. Shah, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas A. Giever, DO
	Dr. James T. Casper, MD This Doctor is OpenDoctor Recommended.
	Dr. Veronica H. Flood, MD This Doctor is OpenDoctor Recommended.
	Dr. Sridhar Rao, MD This Doctor is OpenDoctor Recommended.
	Dr. Mary Eapen, MD This Doctor is OpenDoctor Recommended.
	Dr. Anna Vinitsky, MD This Doctor is OpenDoctor Recommended.
	Mehraboon S. Irani, MB BCH This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog